YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Marcio De'SouzaChief Financial Officer - Tim KellyPresident of Research and Development - Steve PetrouChie…
The pharmaceutical sector differs from many industries as stock performance often depends less on near-term results and more on the success of products in development. For biotech companies, clinical and regulatory developments can sharply…
Insmed stock led a biotech rally Thursday, catapulting 34% on solid second-quarter sales for its new lung disease drug, Brinsupri. Continue Reading
Insmed stock led a biotech rally Thursday, catapulting 30% on solid second-quarter sales for its new lung disease drug, Brinsupri. Continue Reading
* Praxis Precision Medicines (PRAX [https://seekingalpha.com/symbol/PRAX]) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. * The consensus EPS Estimate is -$3.69 [https://seekingalpha.com/symbol/PR…
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 affordable biotech stocks to buy right now. On July 7, Praxis Precision Medicines Inc. (NASDAQ:PRAX) and Remagine Labs disclosed a research partnership and license agreement to…
[Encephalopathy Handwritten on Chalkboard. 3D Illustration] Tashatuvango/iStock via Getty Images * The US FDA has extended the review period for Praxis Precision Medicines' (PRAX [https://seekingalpha.com/symbol/PRAX]) application for relu…
(RTTNews) - Praxis Precision Medicines, Inc. (PRAX) rose in trading after the U.S. FDA granted Breakthrough Therapy Designation to Elsunersen for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy (S…
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 best AI driven biotech stocks to invest in. On June 2, BTIG reduced the price target on Praxis Precision Medicines Inc. (NASDAQ:PRAX) from $843 to $810. The firm maintained a B…
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On June 2, Praxis Precision Medicines Inc. (NASDAQ:PRAX) published the findings of its extensive Phase 2/3 PO…
The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +0.13%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.45%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.48%. June E-mini S&P futures (ESM26) rose +0.14%, and June E-m…
The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +0.13%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.45%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.48%. June E-mini S&P futures (ESM26) rose +0.14%, and June E-m…
Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The S&P 500 Index ($SPX) (SPY) today is up +0.24%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.26%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.29%. June E-mini S&P futures (ESM26) are up +0.20%, and June E-mini Nasdaq futu…
The S&P 500 Index ($SPX) (SPY) today is down -0.20%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.23%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.33%. June E-mini S&P futures (ESM26) are down -0.18%, and June E-mini Nas…
The S&P 500 Index ($SPX) (SPY) today is up +0.24%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.26%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.29%. June E-mini S&P futures (ESM26) are up +0.20%, and June E-mini Nasdaq futu…
The S&P 500 Index ($SPX) (SPY) today is down -0.20%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.23%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.33%. June E-mini S&P futures (ESM26) are down -0.18%, and June E-mini Nas…
(RTTNews) - Biotech stocks are showing strong pre-market moves this Tuesday, hinting at possible breakout setups. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premarket Gainers On Tuesd…
(RTTNews) - Praxis Precision Medicines Inc. (PRAX) announced topline results from its Phase 2/3 POWER1 study of Vormatrigine in adults with focal onset seizures. Focal onset seizures (FOS) are a common form of epilepsy, often requiring mul…
Key Points Exome sold 421,488 shares of Wave Life Sciences; the estimated trade size was $5.49 million based on quarterly average prices. The quarter-end value of the position decreased by $7.17 million as a result. This transaction repres…
On May 15, 2026, Exome Asset Management reported selling out of Wave Life Sciences(NASDAQ:WVE), liquidating 421,488 shares in an estimated $5.49 million trade based on quarterly average pricing. What happened According to an SEC filing dat…
What happened According to an SEC filing dated May 15, 2026, Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in the first quarter. The estimated value of the trade was $4.11 million, based on the quarte…
Key Points Reduced stake by 140,000 shares; estimated transaction value of $4.11 million based on quarterly average price Quarter-end position value fell by $5.18 million, reflecting both trading and stock price changes Post-trade holding:…
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best mid cap stocks to buy with highest upside potential. On May 7, Praxis Precision Medicines reported progress in its clinical pipeline and regulatory milestones during Q1 2026.…
According to the SEC filing dated May 15, Acuta Capital Partners, LLC disclosed a first-quarter sale of 460,887 shares of Ocular Therapeutix(NASDAQ:OCUL). Reduced Ocular Therapeutix holdings by 460,887 shares Post-trade: 592,108 shares hel…
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is one of the 10 Best Performing Canadian Stocks So Far in 2026. On May 12, 2026, JPMorgan analyst Tessa Romero raised the firm’s price target on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to $80 from…
B Group, Inc. disclosed a new stake in Bright Minds Biosciences(NASDAQ:DRUG) in its May 15, 2026, SEC filing, acquiring 67,500 shares—an estimated $5.43 million trade based on quarterly average pricing. What happened According to a May 15,…
On May 15, 2026, HighVista Strategies disclosed it sold 70,503 shares of Maze Therapeutics(NASDAQ:MAZE) in Q1 2026, an estimated $3.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C…
Key Points HighVista increased its Tyra Biosciences holding by 96,218 shares in the first quarter; the estimated trade size was $3.11 million (based on quarterly average prices). The quarter-end position value rose by $4.11 million, reflec…
On May 15, 2026, HighVista Strategies disclosed a purchase of 96,218 shares of Tyra Biosciences(NASDAQ:TYRA), estimated at $3.11 million based on quarterly average pricing. What happened According to its SEC filing dated May 15, 2026, High…
Key Points HighVista Strategies sold 238,243 shares of Viridian Therapeutics; the estimated trade size was $7.08 million based on average closing prices from January through March 2026. The quarter-end position value decreased by $8.97 mil…
HighVista Strategies reported a sale of 238,243 shares of Viridian Therapeutics(NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing. What happened According to a SEC filing date…
HighVista Strategies sold 69,092 shares of Structure Therapeutics(NASDAQ:GPCR) in the first quarter, an estimated $4.73 million trade based on quarterly average pricing, per the May 15, 2026 SEC filing. What happened According to an SEC fi…
On May 15, 2026, Cormorant Asset Management disclosed a buy of 313,645 shares of Alumis(NASDAQ:ALMS), with the estimated transaction value at $7.84 million based on quarterly average pricing. What happened According to a May 15, 2026 SEC f…
On May 15, 2026, Cormorant Asset Management disclosed a new position in Dianthus Therapeutics(NASDAQ:DNTH), acquiring 950,000 shares in an estimated $55.01 million trade based on quarterly average pricing. What happened According to a Secu…